RG 6149

Drug Profile

RG 6149

Alternative Names: AMG 282; RG6149

Latest Information Update: 08 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amgen
  • Developer Amgen; Genentech
  • Class Antiasthmatics; Antibodies; Bronchodilators
  • Mechanism of Action Interleukin 1 receptor-like 1 protein antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Asthma
  • Phase I Allergic asthma; Rhinosinusitis

Most Recent Events

  • 30 Sep 2016 Phase-II clinical trials in Asthma (Adjunctive treatment) (SC) (Roche Presentation, February 2017)
  • 31 May 2016 Amgen completes a phase I trial for Rhinosinusitis with nasal polyps in USA (NCT02170337)
  • 19 Apr 2016 AMG 282 licensed to Genentech (Roche Presentation, April 2016) before April 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top